## CRL: Charles River Laboratories International, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.15 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: overbought RSI (77).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($205.88)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Charles River Labs stock: quiet grind higher as Wall Street leans cautiously bullish**
- Source: AD HOC NEWS | 20260107T040844 | Somewhat-Bullish | Relevance: 100%
- Charles River Laboratories' stock has shown resilience, edging higher despite biotech volatility, trading in the upper third of its 52-week range. Wall Street analysts maintain a cautiously bullish consensus, citing the company's strong market position and stabilizing biotech funding, with an average target price indicating a 10% upside potential. The company's future trajectory hinges on a healthy biotech funding landscape, regulatory compliance, and successful expansion into higher-margin segments like biologics and gene therapies.

**2. Charles River Labs stock: quiet grind higher as Wall Street leans cautiously bullish**
- Source: AD HOC NEWS | 20260107T035535 | Somewhat-Bullish | Relevance: 100%
- Charles River Laboratories' stock has been quietly rising, showing resilience despite a volatile biotech market. Investors are weighing whether this steady climb signals continued growth or a temporary pause. Wall Street analysts generally hold a cautiously bullish outlook, anticipating steady appreciation rather than dramatic spikes.

**3. Charles River Laboratories stock hits 52-week high at $205.55 By Investing.com**
- Source: Investing.com Australia | 20260105T172457 | Bullish | Relevance: 100%
- Charles River Laboratories International Inc. (CRL) shares reached a 52-week high of $205.55, reflecting strong investor confidence and a 28.83% price return over the last six months, despite the stock's RSI indicating it might be overbought. Analysts anticipate profitability this year with a forecasted EPS of $10.34, and management is actively buying back shares. Recent developments include the conclusion of an SEC investigation without enforcement action and several analyst upgrades, highlighting positive sentiment towards the company.

**4. CRL - CRL: Improving Demand And Segment Reviews Will Balance Risks In Recovery Period**
- Source: Simply Wall Street | 20260105T011353 | Somewhat-Bullish | Relevance: 100%
- Analysts have moderately increased Charles River Laboratories International (CRL) price targets, reflecting cautious optimism about stabilizing growth and improved prospects in core segments. While bullish sentiment points to improved demand and strategic reviews, bearish concerns highlight challenges in revenue growth and potential manufacturing segment sale issues. Valuation remains unchanged at $188.93, with future growth assumptions indicating 2.8% annual revenue growth over the next three years.

**5. Charles River Laboratories International Insiders Placed Bullish Bets Worth US$1.25m**
- Source: Yahoo Finance | 20260106T100805 | Bullish | Relevance: 100%
- Over the past year, insiders at Charles River Laboratories International, Inc. made significant bullish bets, purchasing US$1.3 million worth of shares while selling US$974k. The largest individual purchase was by Chairman James Foster for US$1.0 million, indicating a positive outlook on the company's prospects. Despite no recent insider transactions in the last three months, the overall trend suggests growing insider confidence and alignment with shareholders, who collectively own 1.0% of the company's shares.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $200 | $174 | +15% |
| 2025-12-15 | Barclays | $215 | $210 | +2% |
| 2025-12-15 | JP Morgan | $190 | $165 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Neutral |
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +11%) could attract flows.
- Momentum building: MRS_20 improving +4.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.15 indicates undervaluation relative to growth. Forward P/E 19.8x stretched relative to 7% growth. Analyst sentiment positive (3 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.7B |
| Beta | 1.62 |
| 52W Range | $91.86 - $217.83 |
| Short Interest | 5.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.15 |
| Forward P/E | 19.8 |
| Current P/E | 21.2 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 2.7% to 7.2% (+4.4% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 92nd percentile. MRS_5 at 3.1% confirms short-term momentum alignment. AM_20 at 8.2% shows strong absolute momentum above own 20MA. Outperforming sector by 4.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.95), confirming momentum. RSI overbought at 77, risk of mean reversion. OFD pattern: +SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 7.15% (CS: 92) | Strong |
| RSI_14 | 77.1 | Overbought |
| MACD Histogram | 0.95 | Bullish |
| vs SMA20 | 1.082x | Above |
| vs SMA50 | 1.171x | Above |
| vs SMA200 | 1.362x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $216.82
- **Stop Loss:** $205.88 (5.0% risk)
- **Target:** $238.70 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 109
- **Position Value:** $23,633.38
- **Portfolio %:** 23.63%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk appetite. VIX at 15.38 sits in the normal range (18th percentile of 52-week) with modest upward drift, while yield curve remains positively sloped (+62bps 10Y-3M) supporting risk assets. Breadth at 59.5% shows healthy participation, though elevated put/call ratio (1.12) suggests some hedging activity. FOMC 20 days out provides runway for current conditions to persist.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-08 08:02 | MRS_20*